Epilepsy – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Epilepsy – Pipeline Review, H2 2017’, provides an overview of the Epilepsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Epilepsy

The report reviews pipeline therapeutics for Epilepsy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Epilepsy therapeutics and enlists all their major and minor projects

The report assesses Epilepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Epilepsy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Epilepsy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adamas Pharmaceuticals Inc

Advicenne SA

Aequus Pharmaceuticals Inc

Alexza Pharmaceuticals Inc

Anavex Life Sciences Corp

Aphios Corp

Astellas Pharma Inc

Aucta Pharmaceuticals LLC

Bial – Portela & Ca SA

BioCrea GmbH

BioHealthonomics Inc

Bionomics Ltd

Biovista Inc

Biscayne Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerecor Inc

Eisai Co Ltd

Glialogix Inc

Grifols SA

GW Pharmaceuticals Plc

Idorsia Ltd

Insys Therapeutics Inc

Iproteos SL

Johnson & Johnson

Knopp Biosciences LLC

Lead Discovery Center GmbH

Lipicard Technologies Ltd

Lotus Pharmaceutical Co Ltd

Marathon Pharmaceuticals LLC

Marinus Pharmaceuticals Inc

Medicure Inc

Mitochon Pharmaceuticals Inc

MMJ PhytoTech Ltd

Monosol Rx LLC

Neurocrine Biosciences Inc

NeuroCycle Therapeutics GmbH

Neuron Biopharma SA

NoNO Inc

Novartis AG

OPKO Health Inc

Ovid Therapeutics Inc

Pfizer Inc

Promius Pharma LLC

Proximagen Ltd

PTC Therapeutics Inc

reMYND NV

Retrophin Inc

Sage Therapeutics Inc

Saniona AB

SciFluor Life Sciences LLC

Serina Therapeutics Inc

Shire Plc

SK Biopharmaceuticals Co Ltd

Suda Ltd

Sumitomo Dainippon Pharma Co Ltd

Takeda Pharmaceutical Company Ltd

Taro Pharmaceutical Industries Ltd

The Cell-Factory BVBA

Trillium Therapeutics Inc

Turing Pharmaceuticals AG

UCB SA

Upsher-Smith Laboratories Inc

VistaGen Therapeutics Inc

Vitality Biopharma Inc

Xenon Pharmaceuticals Inc

XERIS Pharmaceuticals Inc

Zogenix Inc

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Epilepsy - Overview 7

Epilepsy - Therapeutics Development 8

Epilepsy - Therapeutics Assessment 31

Epilepsy - Companies Involved in Therapeutics Development 45

Epilepsy - Drug Profiles 81

Epilepsy - Dormant Projects 382

Epilepsy - Discontinued Products 389

Epilepsy - Product Development Milestones 391

Appendix 402

List of Tables

List of Tables

Number of Products under Development for Epilepsy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Products under Development by Companies, H2 2017 (Contd..7), H2 2017

Products under Development by Companies, H2 2017 (Contd..8), H2 2017

Products under Development by Companies, H2 2017 (Contd..9), H2 2017

Products under Development by Universities/Institutes, H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Epilepsy – Pipeline by Adamas Pharmaceuticals Inc, H2 2017

Epilepsy – Pipeline by Advicenne SA, H2 2017

Epilepsy – Pipeline by Aequus Pharmaceuticals Inc, H2 2017

Epilepsy – Pipeline by Alexza Pharmaceuticals Inc, H2 2017

Epilepsy – Pipeline by Anavex Life Sciences Corp, H2 2017

Epilepsy – Pipeline by Aphios Corp, H2 2017

Epilepsy – Pipeline by Astellas Pharma Inc, H2 2017

Epilepsy – Pipeline by Aucta Pharmaceuticals LLC, H2 2017

Epilepsy – Pipeline by Bial – Portela & Ca SA, H2 2017

Epilepsy – Pipeline by BioCrea GmbH, H2 2017

Epilepsy – Pipeline by BioHealthonomics Inc, H2 2017

Epilepsy – Pipeline by Bionomics Ltd, H2 2017

Epilepsy – Pipeline by Biovista Inc, H2 2017

Epilepsy – Pipeline by Biscayne Pharmaceuticals Inc, H2 2017

Epilepsy – Pipeline by Catalyst Pharmaceuticals Inc, H2 2017

Epilepsy – Pipeline by Cerecor Inc, H2 2017

Epilepsy – Pipeline by Eisai Co Ltd, H2 2017

Epilepsy – Pipeline by Glialogix Inc, H2 2017

Epilepsy – Pipeline by Grifols SA, H2 2017

Epilepsy – Pipeline by GW Pharmaceuticals Plc, H2 2017

Epilepsy – Pipeline by Idorsia Ltd, H2 2017

Epilepsy – Pipeline by Insys Therapeutics Inc, H2 2017

Epilepsy – Pipeline by Iproteos SL, H2 2017

Epilepsy – Pipeline by Johnson & Johnson, H2 2017

Epilepsy – Pipeline by Knopp Biosciences LLC, H2 2017

Epilepsy – Pipeline by Lead Discovery Center GmbH, H2 2017

Epilepsy – Pipeline by Lipicard Technologies Ltd, H2 2017

Epilepsy – Pipeline by Lotus Pharmaceutical Co Ltd, H2 2017

Epilepsy – Pipeline by Marathon Pharmaceuticals LLC, H2 2017

Epilepsy – Pipeline by Marinus Pharmaceuticals Inc, H2 2017

Epilepsy – Pipeline by Medicure Inc, H2 2017

Epilepsy – Pipeline by Mitochon Pharmaceuticals Inc, H2 2017

Epilepsy – Pipeline by MMJ PhytoTech Ltd, H2 2017

Epilepsy – Pipeline by Monosol Rx LLC, H2 2017

Epilepsy – Pipeline by Neurocrine Biosciences Inc, H2 2017

Epilepsy – Pipeline by NeuroCycle Therapeutics GmbH, H2 2017

Epilepsy – Pipeline by Neuron Biopharma SA, H2 2017

Epilepsy – Pipeline by NoNO Inc, H2 2017

Epilepsy – Pipeline by Novartis AG, H2 2017

Epilepsy – Pipeline by OPKO Health Inc, H2 2017

Epilepsy – Pipeline by Ovid Therapeutics Inc, H2 2017

Epilepsy – Pipeline by Pfizer Inc, H2 2017

Epilepsy – Pipeline by Promius Pharma LLC, H2 2017

Epilepsy – Pipeline by Proximagen Ltd, H2 2017

Epilepsy – Pipeline by PTC Therapeutics Inc, H2 2017

Epilepsy – Pipeline by reMYND NV, H2 2017

Epilepsy – Pipeline by Retrophin Inc, H2 2017

Epilepsy – Pipeline by Sage Therapeutics Inc, H2 2017

Epilepsy – Pipeline by Saniona AB, H2 2017

Epilepsy – Pipeline by SciFluor Life Sciences LLC, H2 2017

Epilepsy – Pipeline by Serina Therapeutics Inc, H2 2017

Epilepsy – Pipeline by Shire Plc, H2 2017

Epilepsy – Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017

Epilepsy – Pipeline by Suda Ltd, H2 2017

Epilepsy – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017

Epilepsy – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Epilepsy – Pipeline by Taro Pharmaceutical Industries Ltd, H2 2017

Epilepsy – Pipeline by The Cell-Factory BVBA, H2 2017

Epilepsy – Pipeline by Trillium Therapeutics Inc, H2 2017

Epilepsy – Pipeline by Turing Pharmaceuticals AG, H2 2017

Epilepsy – Pipeline by UCB SA, H2 2017

Epilepsy – Pipeline by Upsher-Smith Laboratories Inc, H2 2017

Epilepsy – Pipeline by VistaGen Therapeutics Inc, H2 2017

Epilepsy – Pipeline by Vitality Biopharma Inc, H2 2017

Epilepsy – Pipeline by Xenon Pharmaceuticals Inc, H2 2017

Epilepsy – Pipeline by XERIS Pharmaceuticals Inc, H2 2017

Epilepsy – Pipeline by Zogenix Inc, H2 2017

Epilepsy – Pipeline by Zynerba Pharmaceuticals Inc, H2 2017

Epilepsy – Dormant Projects, H2 2017

Epilepsy – Dormant Projects, H2 2017 (Contd..1), H2 2017

Epilepsy – Dormant Projects, H2 2017 (Contd..2), H2 2017

Epilepsy – Dormant Projects, H2 2017 (Contd..3), H2 2017

Epilepsy – Dormant Projects, H2 2017 (Contd..4), H2 2017

Epilepsy – Dormant Projects, H2 2017 (Contd..5), H2 2017

Epilepsy – Dormant Projects, H2 2017 (Contd..6), H2 2017

Epilepsy – Discontinued Products, H2 2017

Epilepsy – Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

List of Figures

Number of Products under Development for Epilepsy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports